Alnylam Pharmaceuticals shares fall more than 40% year-to-date despite improved profitability
ALNY Alnylam Pharmaceuticals Inc
$230.71 -1.11%
View chart & analysis → - 1Alnylam shares have recorded a decline of more than 40% since the beginning of the year.
- 2Alnylam's GAAP net income for the second quarter was $164.5 million.
- 3CEO Yves Greenstreet lowered the 2026 annual revenue guidance for Amvuttra and Onpattra from $4.2 billion to $4.5 billion.
So what's the key point?
Alnylam made a profit, but its stock price has fallen more than 40% this year. The stock price is struggling as expected drug sales forecasts were lowered.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.